Second DCIS Diagnoses May Not Be Related to Initial Lesion
DNA sequencing found that in many cases when DCIS recurred, the lesion was unrelated to the first diagnosis, raising questions about how to best treat recurrence.
Progress Against Cancer
DNA sequencing found that in many cases when DCIS recurred, the lesion was unrelated to the first diagnosis, raising questions about how to best treat recurrence.
Expansions in coverage and eligibility through the Affordable Care Act have made Medicaid a lifeline for many people with cancer, but benefits vary from state to state.
Different types of colorectal polyps can be difficult to distinguish, a new AI program improved pathologists' accuracy in a recent study.
Research suggests short bursts of intense calorie restriction could improve treatment response in patients with a range of cancers.
Success of immune checkpoint inhibitors in clinical trials does not always carry over to patients in the clinic.
Metastatic prostate cancer incidence rose after recommendation against routine screening, and FDA approves first PARP inhibitor for early-stage breast cancer for people with inherited BRCA mutations.
A new report from the American Association for Cancer Research explores how the COVID-19 pandemic affected cancer patients, researchers and care providers.
A new kind of blood test could help detect brain cancers at an earlier stage.
Results favor Enhertu for treating metastatic breast cancer that recurs or does not respond to first-line treatment.
Metastatic cancer patients nearing death continue to receive high-dose radiation despite guidelines advising against it, and new standards are likely to reduce racial disparities in lung cancer screening.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More